Business & Tech

Milford Biotech Company Plans Another Local Expansion

​The expansion follows a $225 million investment by Nitto Denko Avecia​'s parent company announced last March.

The new Nitto Denko Avecia building in Milford.
The new Nitto Denko Avecia building in Milford. (Business Wire)

MILFORD, MA — A planned expansion at a Milford biotechnology facility will head to the Planning Board this week.

Nitto Denko Avecia, owned by Japan-based Nitto, is investing about $225 million in its U.S. facilities, including one in Milford along Fortune Boulevard. The facility is Nitto's U.S. headquarters, and serves as a research and development center for oligonucleotides — therapies that use DNA and RNA, similar to the Pfizer and Moderna coronavirus vaccines.

The company is in the process of rebuilding its Milford headquarters, which the town signed off on in 2020.

Find out what's happening in Milfordfor free with the latest updates from Patch.

The company will go before the Planning Board on Thursday for approval to expand the number of parking spaces at the Fortune Boulevard building. The company wants to add 154 new spaces for a total of 368 spaces.

Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.